Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma

Izidore S Lossos, Carol D Jones, Roger Warnke, Yasodha Natkunam, Herbert Kaizer, James L Zehnder, Rob Tibshirani, Ronald Levy
2001-08-15
Abstract:Diffuse large B-cell lymphoma (DLBCL) is characterized by a marked degree of morphologic and clinical heterogeneity. Establishment of parameters that can predict outcome could help to identify patients who may benefit from risk-adjusted therapies. BCL-6 is a proto-oncogene commonly implicated in DLBCL pathogenesis. A real-time reverse transcription–polymerase chain reaction assay was established for accurate and reproducible determination of BCL-6 mRNA expression. The method was applied to evaluate the prognostic significance ofBCL-6 expression in DLBCL. BCL-6 mRNA expression was assessed in tumor specimens obtained at the time of diagnosis from 22 patients with primary DLBCL. All patients were subsequently treated with anthracycline-based chemotherapy regimens. These patients could be divided into 2 DLBCL subgroups, one with high BCL-6 gene expression whose median overall …
What problem does this paper attempt to address?